Last reviewed 2026-05-21 · How we verify

Ambusid (AMBUSIDE)

Phase 2 active Small molecule ✓ Verified May 2026

Ambusid (generic name: AMBUSIDE) is a ambuside drug. It is currently in Phase 2 development.

Ambuside works by interacting with a specific biological target to produce a therapeutic effect.

Ambusid is a small molecule. It is also known by the synonyms AMBUSIDA, AMBUSIDE, AMBUSIDE, AMBUSIDE, EX 4810, and EX-4810.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AMBUSIDE
Drug class	ambuside
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine ambuside as a key that fits into a lock on a cell. When it binds to the lock, it triggers a series of events that ultimately lead to the desired outcome, such as reducing symptoms of a particular disease. However, the exact details of how ambuside interacts with its target are not yet fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ambusid CI brief — competitive landscape report
Ambusid updates RSS · CI watch RSS

Frequently asked questions about Ambusid

What is Ambusid?

Ambusid (AMBUSIDE) is a ambuside drug.

How does Ambusid work?

Ambuside works by interacting with a specific biological target to produce a therapeutic effect.

What is the generic name of Ambusid?

AMBUSIDE is the generic (nonproprietary) name of Ambusid.

What drug class is Ambusid in?

Ambusid belongs to the ambuside class. See all ambuside drugs at /class/ambuside.

What development phase is Ambusid in?

Ambusid is in Phase 2.

Drug class: All ambuside drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing